REG - BSF Enterprise PLC - Showcase Meat Update

BSF EnterpriseAnnouncement

21/04/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230421:nRSU9827Wa&default-theme=true

RNS Number : 9827W  BSF Enterprise PLC  21 April 2023

21 April 2023

BSF Enterprise PLC

("BSF" or the "Company")

 

Showcase Meat Update

 

BSF Enterprise plc (LSE: BSFA), a company focused on unlocking the next
generation of biotech solutions, is pleased to announce that its wholly owned
subsidiary, 3D Bio-Tissues (3DBT), is making positive progress in relation to
the development of its products and is on track to produce and display the
full-scale 100% meat fillet of cultivated pork, as well as a series of 100%
new meat strips of cultivated pork, which will be showcased before the end of
H1 2023.

In producing these fillets and strips, the team is building on the technical
findings and data collected from the development of the Company's first
full-scale fillet, as announced in January 2023. Once produced, the products
will undergo testing at a technical event organised by the Company, to which
key shareholders will be invited. The testing will involve data collection,
inspection and analysis of the product in raw and cooked state. More details
will be released closer to the showcase event.

Cellular Agriculture Manufacturing Hub

The Company is also pleased to announce that 3DBT has become a project partner
at the Cellular Agriculture Manufacturing Hub led by the University of Bath.
This £12m UK government-funded hub is bringing together leading academic and
industrial experts to accelerate and solidify the UK's position in cultured
meat production. 3DBT will be working alongside other project partners and
supporting them by providing its cell and tissue-enhancing City-Mix(TM)
products.

Che Connon, Chief Executive of 3DBT, said: "We are very pleased with the
progress being made in our Newcastle laboratory, as we apply the findings from
growing our prototype fillets and strips to refine City-Mix(TM) our patented
animal-free cell-boosting medium, and its application. We are excited to share
this scientific milestone with the industry and market in the coming months.

 

"Our activities are attracting attention in the industry, as demonstrated by
our recent appointment as a project partner on a recently announced Cellular
Agriculture Manufacturing Hub. We are looking forward to working alongside
other project partners and supporting them with our cell and tissue-enhancing
products and technologies."

 

 

For further enquiries, please visit www.bsfenterprise.com
(http://www.bsfenterprise.com/)  or contact:

 BSF Enterprise PLC                       Via SEC Newgate below
 Geoff Baker - Non-Executive Director

 Che Connon - Executive Director

 Shard Capital (Broker)
 Damon Heath                              02071869927

 Isabella Pierre

 SEC Newgate (Financial Communications)
 Bob Huxford                              020 3757 6882

 Elisabeth Cowell                         BSF@secnewgate.co.uk

 George Esmond

 

ISIN of the Ordinary Shares is GB00BHNBDQ51

SEDOL Code is BHNBDQ5.

 

Notes to Editors

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of
biotechnological solutions - using cell-based tissue engineering to help
generate cultured meat, lab-grown leather, as well as human corneas, collagen
growth and skin substitutes, as part of a radical transformation to deliver
sustainable solutions across a variety of sectors.

 

It owns 100% of 3D Bio-Tissues (3DBT), a tissue engineering with
patent-protected IP that is already producing human corneas to help restore
vision to millions of people. Building on this success, it aims to
produce the UK's first high quality lab-grown meat from its laboratory in
Newcastle the next 12 months, transforming the meat-production industry
towards an ethical and sustainable practice.

 

BSF aims to deliver growth to shareholders through the continued
commercialisation of 3DBT's IP, which has multiple applications, as well as
through M&A. It aims to acquire a suite of technologies that underpins the
development of tissue templating for corneas, meat and leather, and license
out the IP to manufacturers, wholesalers and distributors to help manufacture
the products at scale.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPPURWCUPWGBU